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ABSTRACT
Aim Differentiating physiological cardiac hypertrophy
from pathology is challenging when the athlete presents
with extreme anthropometry. While upper normal limits
exist for maximal left ventricular (LV) wall thickness
(14 mm) and LV internal diameter in diastole (LVIDd,
65 mm), it is unknown if these limits are applicable to
athletes with a body surface area (BSA) >2.3 m2.
Purpose To investigate cardiac structure in professional
male athletes with a BSA>2.3 m2, and to assess the
validity of established upper normal limits for
physiological cardiac hypertrophy.
Methods 836 asymptomatic athletes without a family
history of sudden death underwent ECG and
echocardiographic screening. Athletes were grouped
according to BSA (Group 1, BSA>2.3 m2, n=100;
Group 2, 2–2.29 m2, n=244; Group 3, <1.99 m2, n=492).
Results There was strong linear relationship between BSA
and LV dimensions; yet no athlete with a normal ECG
presented a maximal wall thickness and LVIDd greater than
13 and 65 mm, respectively. In Group 3 athletes, Black
African ethnicity was associated with larger cardiac
dimensions than either Caucasian or West Asian ethnicity.
Three athletes were diagnosed with a cardiomyopathy
(0.4% prevalence); with two athletes presenting a maximal
wall thickness >13 mm, but in combination with an
abnormal ECG suspicious of an inherited cardiac disease.
Conclusion Regardless of extreme anthropometry,
established upper limits for physiological cardiac
hypertrophy of 14 mm for maximal wall thickness and
65 mm for LVIDd are clinically appropriate for all athletes.
However, the abnormal ECG is key to diagnosis and guides
follow-up, particularly when cardiac dimensions are within
accepted limits.
INTRODUCTION
Regular and prolonged intensive exercise is asso-
ciated with cardiac morphological adaptation,
together with electrocardiographic alterations.1–4
Signiﬁcant cardiac enlargement may be an expres-
sion of underlying cardiac disease, placing the
athlete at a greater risk of sudden cardiac death
(SCD).5 In rare cases, the degree of physiological
adaptation in cardiac morphology can mimic that
of a number of pathological disease states, most
notably hypertrophic cardiomyopathy (HCM).6
Differentiation between a physiological or patho-
logical remodelling process is, therefore, extremely
important. Consequently, establishing the upper
normal limits of physiological enlargement in
response to physical training is an important focus
for clinicians and scientists.
Fourteen and 65 mm have been established as the
physiological upper limits for maximal wall thick-
ness and left ventricular (LV) internal diameter
during diastole, respectively. These limits come
from three large-scale studies examining approxi-
mately 4800 elite athletes (predominantly male),
who observed that a small minority (1.5–4%) dem-
onstrate LV hypertrophy (LVH) >13 mm and 4–6%
have an LVend-diastolic dimension >60 mm. What
this minority of athletes with pronounced LVH
have common is an enlarged BSA (approximate
mean BSA 2.1 m2).4 7 8 However, despite recognis-
ing that the largest maximal wall thicknesses are
observed in those with the largest BSA’s, there
are limited data examining the impact of extreme
body anthropometry (BSA>2.3 m2) upon cardiac
morphology in professional athletes. This is
important as it is widely recognised that LV dimen-
sions are inﬂuenced by body anthropometry.9 10
Pluim et al2 was the ﬁrst to recognise the import-
ance of BSA when undertaking preparticipation
screening, suggesting that the probability of false-
positive HCM identiﬁcation would be exacerbated
in athletes with a BSA>2 m2. Basketball, handball
and volleyball are three such sports whereby some
male athletes may exceed the stereotypical anthro-
pometry for an athlete; with heights and body
mass’s reaching 220 cm and 150 kg, respectively.11 12
Magalski et al13 electrocardiographic examination
of 1959 American Football players was one of the
largest studies to undertake preparticipation screen-
ing in athletes with large anthropometry (mean
BSA; 2.4±0.3 m2). Regrettably, only 203 American
Football players received an echocardiogram follow-
ing a referral due to an abnormal ECG, family
history or clinical examination, with the BSA of
this cohort unreported.
The aim of the present study was to investigate
the cardiac structure and function in professional
male athletes with extreme anthropometry
(≥2.3 m2), to conﬁrm if the established upper
limits of physiological cardiac adaptation to inten-
sive and sustained physical activity are applicable
for this unique population.
METHODS
Ethical approval was obtained from the Shafallah
Medical Genetics Centre ethics committee, with
all athletes completing informed consent.
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Participants
836 asymptomatic professional male athletes (age 25±8 years),
exercising ≥6 h/week in 15 high-intensity intermittent sporting
disciplines (eg, Soccer, n=586; basketball, n=75; volleyball,
n=41 and handball, n=35) presented at our institution for pre-
participation cardiac screening (table 1). Athletes were cate-
gorised into three distinct groups according to their body
surface area14 (DuBois and DuBois, 1916); Group 1
BSA>2.3 m2 (n=100, 197±9 cm and 105±12 kg); Group 2 BSA
2–2.29 m2 (n=244, 184±6 cm and 83±6 kg) and Group 3
BSA<1.99 m2 (n=492, 172±6 cm and 66±8 kg). Strict exclu-
sion criteria included athletes who had undergone previous pre-
participation cardiovascular screening with electrocardiography
and echocardiography, and those athletes currently experiencing
symptoms suggestive of cardiovascular disease and/or demon-
strating an early family history of SCD. This was important as
the population truly reﬂected those individuals who had not
been excluded from competitive sport on the suspicion of har-
bouring an inherited cardiac pathology. As previously
described,15 16 the term ‘West-Asian’ denotes individuals of
Gulf or Middle-Eastern descent, and ‘Black African’ denotes
individuals of African descent. West-Asian athletes were
recruited from seven Gulf States (Qatar, Bahrain, Oman, UAE,
Kuwait, Yemen and Saudi Arabia) and six Middle-Eastern coun-
tries (Egypt, Jordan, Palestine, Iraq and Lebanon). Black athletes
from seven African countries (Sudan, Somalia, Ghana, Nigeria,
Ivory Coast Senegal, Cameroon and Ethiopia) were also
recruited alongside Caucasian athletes from the USA, Canada,
Australia, Russia, Bosnia and Croatia.
Physical examination
The physical examination was based on the European Society
of Cardiology (ESC) sport’s cardiology section consensus state-
ment.11 Players completed the questionnaire regarding family
history and personal symptoms in collaboration with an
Arabic-speaking, French-speaking or English-speaking Sports
Medicine Physician and Nurse. Measurement of height (SECA
264, Hamburg, Germany), body mass (Detecto 6129KGM,
Missouri, USA), brachial artery blood pressure (GE Dinamap
Pro 400V2, New York, USA) in the supine position (both left
and right arms) after a period of 5 min rest, precordial ausculta-
tion in supine and standing positions, and assessment for any
physical characteristics of Marfan’s syndrome were undertaken
by a Sports Medicine Physician.
Resting 12-lead ECG
A standard 12-lead ECG was obtained using a GE Mac 5500
(New York, USA) after a period of 5 min rest in the supine pos-
ition. All ECG’s were reported independently by two experi-
enced investigators (OS and MW) using the recent 2010 ESC
recommendations for interpretation of 12-lead electrocardio-
gram in the athlete,17 with third opinions sought from two
international cardiologists (SS and FC) for difﬁcult cases.
Echocardiography
A two-dimensional (2D), M-mode and Doppler and tissue
Doppler echocardiographic examination was performed in the
left lateral decubitas position by a consultant cardiologist using
a commercially available ultrasound system (Philips, USA).
Images of the heart were obtained in the standard parasternal
long-axis and short-axis and apical four-chamber planes, as pre-
viously described,18 in order to identify subtle focal regions of
abnormal LV hypertrophy. The LV wall thickness was measured
from 2D short-axis views in end-diastole, with the greatest
measurement within the LV wall deﬁned as the maximal wall
thickness. M-mode echocardiograms derived from 2D images in
the parasternal long axis were used for the measurement of LV
end-diastolic diameter (LVIDd) and LV end-systolic (LVIDs)
dimensions, left atrial diameter and aortic root diameter accord-
ing to American Society of Echocardiography standards,19 with
LV volumes (diastolic and systolic) derived using Simpson’s
biplane methodology. Left ventricular mass was calculated
using the formula of Devereux.20 Three to ﬁve consecutive
measurements were taken, and the average was calculated. Left
ventricular diastolic function was assessed using pulsed-wave
Doppler recordings from apical four-chamber orientations. A
4 mm sample volume was placed at the tips of the mitral leaf-
lets in diastole and transmitral ﬂow was acquired to obtain
peak early (E) and atrial (A) ﬂow velocities. All data was ana-
lysed ofﬂine and a minimum of three cardiac cycles were aver-
aged for all indices. For the tissue Doppler assessment of E’, the
apical four-chamber orientation was utilised and a 2 mm
sample volume was positioned at both the septal and lateral
wall aspect of the mitral valve annulus ensuring the best align-
ment between wall motion and the ultrasound beam. The
high-pass ﬁlter was bypassed and gains set to a minimal value
to obtain the best signal-to-noise ratio. The nyquist limit was
set between 10 and 35 cm/s. Peak early diastolic (E’) tissue
myocardial velocity was recorded and E/E’ was calculated.
Criteria for consideration of the diagnosis of pathological LVH
in athletes
On the basis of previous publications and our own experience of
an athlete’s heart, athletes with an LV wall thickness >12 mm
were considered to have LVH.7 21 22 Athletes with LVH and a
relatively non-dilated LV in terms of athletic training (<56 mm)23
in association with any one of the following were considered to
have ﬁndings that could be consistent with pathological LVH
rather than physiological hypertrophy: (1) impaired diastolic
function;24 (2) enlarged left atrial diameter >45 mm in athletes
Table 1 Demographic data of all athletes categorised by body surface
area (BSA)
Group 1 Group 2 Group 3
BSA>2.3 m2
(n=99)
BSA 2–2.29 m2
(n=244)
BSA<1.99 m2
(n=492)
Age (years) 26.0±5.8
(15–35)
25.1±6.2
(14–35)
23.5±6.2***
(13–37)
Height (cm) 196.8±8.6*
(170–217)
183.7±6.2**
(168–207)
172.5±7.6
(153–191)
Weight (kg) 105.1±12.1*
(85–156)
82.8±5.9**
(66–110)
66.2±7.5
(41–88)
Ethnicity (%)
West-Asian 31 55 76
Black
African
46 35 19
Caucasian 23 10 5
Sport (%)
Football 11.1 68.6 83.0
Basketball 40.4 8.7 2.6
Handball 18.2 7.0 0.8
Volleyball 23.2 7.4 0.0
Other 7.1 8.3 13.4
*Significant difference between BSA>2.3 m2 and other two groups (p<0.05).
**Significant difference between BSA 2–2.29 m2 and BSA<1.99 m2 (p<0.05).
***Significant difference between both BSA>2.3 m2 and BSA 2–2.29 m2 from
BSA<1.99m2 (p<0.05).
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<18-year-old25 and up to 50 mm in older athletes;26 (3) LV
outﬂow obstruction;27 (4) left bundle branch block28 and (5)
ST-segment depression or deep Twave inversions (<−0.2 mV) in
≥2 contiguous anterior, inferior or lateral leads (but not aVR, and
III)29 on the ECG. Athletes demonstrating echocardiographic
and/or ECG abnormalities considered to represent pathological
LVH were investigated further with 48 h ECG,30 cardiopulmon-
ary exercise test31 32 and cardiac MRI33 to evaluate the broader
phenotype of common cardiomyopathic processes such as HCM
and arrhythmogenic right ventricular cardiomyopathy, in add-
ition to assessing the risk of SCD.34
Statistical analysis
All data were presented as mean±SD and (range), and analysed
using SPSS (Statistical Package for Social Sciences 17, Illinois,
USA). Data were analysed using a two-way between-subjects
analysis of variance, with pair-wise comparisons, used to iden-
tify any signiﬁcant differences in athlete anthropometrics and
echocardiographic characteristics between the three BSA
groups, together with athlete anthropometrics and echocardio-
graphic characteristics between Black African, West-Asian and
Caucasian ethnicity in the >2.3 m2 BSA group. Relationships
between data indices of echocardiographic measures of cardiac
structure and function against the athletes BSA together with
their resting systolic blood pressure were examined via Pearson’s
product–moment correlation analysis. A p value <0.05 was
considered signiﬁcant.
RESULTS
None of the athletes experienced angina, breathlessness dispro-
portionate to the amount of exercise performed, or exertional
syncope. The diagnosis of HCM was excluded by echocardiog-
raphy in 819 (98%) on the basis of an LV wall thickness
<12 mm, absence of systolic anterior motion of the anterior
mitral valve leaﬂet causing LV outﬂow obstruction and normal
diastolic function.
Athletes with an LV wall thickness >12 mm (LVH)
Of the 836 athletes, 17 (2%) showed a maximal LV wall thick-
ness exceeding 12 mm and were considered to have LVH.23
Twelve (12%) of these athletes demonstrating LVH came from
the >2.3 m2 BSA cohort, compared with just 3 (1.2%) and 2
(0.4%) from Groups 2 and 3, respectively. All 17 athletes with
LVH had an appropriate (≥45 mm) LV chamber dimension (mean
56±4 mm, (range 49–63)), normal systolic and diastolic function,
an enlarged left atrial diameter and no systolic anterior motion of
the anterior mitral valve leaﬂet or LVoutﬂow obstruction.
Athletes with an LVH >12 mm and an abnormal ECG
Of the 17 athletes with LVH, only 2 (0.2%) demonstrated a
wall thickness that exceeded 13 mm (table 2; athletes 1 and 2).
However, both athletes also demonstrated ECG’s highly suspi-
cious of HCM (ﬁgure 1A,B). Following extensive further inves-
tigation, both athletes were diagnosed with a cardiomyopathy
and were eventually disqualiﬁed from competitive sport. Both
athletes were removed from any further group analysis.
Athletes with other cardiac abnormalities on ECG and
echocardiography
One further athlete (table 2; athlete 3) was diagnosed with a
mild variant of apical HCM, due to disproportionally thickened
apical segments of the basal and septal walls upon cardiac
MRI, following an abnormal ECG (ﬁgure 1C) but normal echo-
cardiogram (maximal basal LV wall thickness of 8 mm). This
athlete was removed from any further group analysis. Four
asymptomatic athletes without cardiac murmur were found to
have trivial valve regurgitation (one mitral, one aortic and two
tricuspid), not requiring further investigation after echocardiog-
raphy. Finally, one asymptomatic player had an aortic root
Table 2 Follow-up results of three athletes presenting with an abnormal ECG on initial screening
Athlete Symptoms
FH of SCD
(<35 year) ECG abnormality Echocardiogram
Exercise Stress
Test and 24 h
Holter ECG CMR
Screened
first-degree
relatives Diagnosis
(1) 19-year-old
West-Asian
footballer (1.99 m2
BSA)
No No RAE, profound
voltage (77 mm),
Q waves in II, III,
aVF, T wave
inversion in I, II,
III, aVL, aVF and
ST segment
depression in II,
III and aVF
Subaortic IVSd
bulge of 20 mm,
without obstruction
of the outflow tract
No arrhythmia
during exercise
with appropriate
BP response. Few
monomorphic PVB
on Holter
monitoring
Asymmetric septal
hypertrophy with a
maximal septal wall
thickness of 20 mm
versus lateral wall of
11 mm without
obstruction. No LGE,
oedema or systolic
dysfunction
Father’s ECG
and Echo
confirmed
HCM
Non-obstructive
HCM
(2) 29-year-old
Black
African-American
basketball player
(2.35 m2 BSA)
No No Profound voltage
in V3, deep T
wave inversion in
V6
Normal apart from
max wall thickness
of 13.6 mm
No arrhythmia
during exercise
with appropriate
BP response
Mild asymmetric
hypertrophy of IVSd
without obstruction
(basal 8 mm, mid
15 mm, apical 9 mm),
associated with
significant mid-septum
transmural fibrosis
Not available Non-obstructive
HCM
No arrhythmia on
Holter
(3) 27-year-old
West-Asian Futsal
player (1.75 m2
BSA)
No No Profound voltage
in V4 (59 mm), T
wave inversion in
II, III, aVF, V2–V6
and ST segment
depression in
V4–V5
Normal (max wall
thickness 8.2 mm)
No arrhythmia
during exercise
with appropriate
BP response
Apical segments are
disproportionally
thickened, increased
basal and septal wall
thickness. No LGE,
oedema or systolic
dysfunction
Not available Mild variant of
apical HCM
No arrhythmia on
Holter
BP, blood pressure; BSA, body surface area; CMR, cardiac magnetic resonance imaging; FH, family history; HCM, hypertrophic cardiomyopathy; IVSd, intraventricular septum in
diastole; LGE, late gadolinium enhancement; PVB, premature ventricular beats; RAE, right atrial enlargement; SCD, sudden cardiac death.
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dimension at the upper limit of normal but given the borderline
measure and normality of other parameters, was provided
medical clearance and requested to attend yearly echocardio-
graphic examination. These last ﬁve athletes remained in the
group analysis.
Impact of BSA upon cardiac structure and function
A signiﬁcant and progressive increase in aortic, left and right
atrial, as well as left and right ventricular dimensions and
volumes was observed as BSA increased (table 3; p<0.05). No
athlete with a normal ECG demonstrated a maximal wall
thickness >13 mm and an LVIDd>65 mm. A total of 36 ath-
letes (4% overall) had an LVIDd>60 mm; of which 19 (19%)
came from Group 1 compared to 13 (5%) and 4 (0.8%) from
Groups 2 and 3, respectively. A signiﬁcantly higher peak early
diastolic mitral ﬂow velocity was observed in Group 3 com-
pared to the two other BSA groups (p<0.05). Furthermore, a
peak early mitral annular velocity of the septal wall was signiﬁ-
cantly lower in Group 1 athletes than the other two BSA
groups (p<0.05). No other cardiac functional measures were
signiﬁcantly different between BSA groups. Finally, a signiﬁcant
linear relationship (r=0.3, p<0.0001) was observed between the
athletes BSA and their systolic blood pressure (ﬁgure 2), and
between systolic blood pressure and IVSd (r=0.49), LVIDd
(r=0.54), posterior wall thickness in diastole (PWTd) (r=0.51)
and LVM (r=0.69, p<0.0001).
Impact of ethnicity upon cardiac structure and function in
athletes with a BSA>2.3 m2
Of the 99 remaining athletes in the BSA>2.3 m2 cohort (31
West-Asian, 45 Black African and 23 Caucasian athletes), there
were no signiﬁcant differences in BSA between the three ethnici-
ties. Black African athletes had a signiﬁcantly thicker IVSd and
PWTd than both West-Asian and Caucasian athletes (p<0.05).
Black African athletes also had signiﬁcantly larger LAvolumes, RA
areas and LV masses than West-Asian athletes (p<0.05).
West-Asian athletes had a signiﬁcantly larger LVIDd than
Caucasian athletes (p<0.05). There were no signiﬁcant differences
between ethnicities in any diastolic or systolic parameter (table 4).
DISCUSSION
The main ﬁnding of the current study was that the upper
normal limits for maximal LV dimensions in professional
male athletes with extreme anthropometric characteristics
(BSA>2.3 m2) remains 14 mm for maximal wall thickness and
65 mm for LV internal diameter during diastole. Furthermore,
Figure 1 (A)–(C) Twelve-lead ECG and cardiac magnetic resonance images of two athletes (1 and 2) with a maximal wall thickness greater than
13 mm, and one athlete (3) with a maximal wall thickness of 8.2 mm on echocardiography, yet apical segments do not show normal tapering
pattern and are disproportionately thickened on CMR imaging. Arrow (athlete 2) points to localised ﬁbrosis of the septal wall at the mid-cavity level.
This ﬁgure is only reproduced in colour in the online version.
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for those athletes with the largest BSA’s, Black African ethni-
city was associated with larger cardiac dimensions than either
West-Asian or Caucasian ethnicity. Finally, in a sample of 836
athletes, 3 were diagnosed with a cardiomyopathy; 0.4% preva-
lence rate that in all cases, the ECG was vital for the initial
identiﬁcation and eventual diagnosis of the disease.
From four large-scale echocardiographic studies examining a
total of 5053 elite athletes,4 7 8 35 only 134 athletes (2.7%) demon-
strated a maximal wall thickness greater than 12 mm, with only a
further 27 athletes (0.5%) presenting LVH>13 mm. However, out
of these 5053 athletes the largest end of range BSA’s in all four
studies varied from 2.26 to 2.29 m2, with only one athlete from
Figure 1 (Continued)
Table 3 Cardiac structural variables compared between BSA categories (mean±SD; range)
Group 1 Group 2 Group 3
BSA>2.3 m2 (n=99) BSA 2–2.29 m2 (n=243) BSA<1.99 m2 (n=491)
Aortic diameter (mm) 30±2* (25–35) 28±2** (23–39) 26±2 (19–33)
LA (mm) 37±4* (28–48) 35±3** (26–47) 32±4 (21–42)
LA area (mm2) 223±4* (14–33) 20±3** (13–31) 18±4 (10–30)
LA volume (ml) 66±17* (23–103) 58±15** (26–118) 46±12 (18–96)
Right atrial area (mm2) 20±3* (12±28) 18±3** (12–28) 15.6±5.8 (8–26)
Right ventricular internal diameter in diastole (mm) 22±5* (14–40) 19±4** (4–34) 17±3 (9–32)
Interventricular septum thickness in diastole (mm) 10±1* (7–13) 9±01** (7–12) 9±1 (6–12)
Posterior wall thickness in diastole (mm) 9±1* (7–13) 9±1** (6–11) 8±1 (5–11)
LVID in diastole (mm) 57±3* (48–63) 55±3** (42–65) 52±4 (40–62)
LVID in systole (mm) 40±5* (26–50) 39±4** (27–47) 37±4 (25–62)
LV end diastolic volume (ml) 155±30* (88–271) 133±23** (68–216) 114±22 (11–196)
LVE end systolic volume (ml) 50±12* (22–111) 45±10** (21–76) 38±10 (14–98)
LV mass (g) 223±39* (140–348) 190±28** (123–286) 157±30 (66–241)
*Significant difference between BSA>2.3 m2 and other two groups (p<0.05).
**Significant difference between BSA 2–2.29 m2 and BSA<1.99 m2 (p<0.05).
LA, left atrial diameter; LVID, left ventricular internal diameter.
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Whyte et al4 study presenting a BSA of 2.52 m2. This study pre-
sents 100 professional male athletes with a BSA>2.3 m2 (mean 2.4
±0.1 m2). Only one athlete from this cohort demonstrated
LVH>13 mm, but he also exhibited a particular abnormal ECG
suggestive of an inherited cardiac disease, and was eventually diag-
nosed with HCM via cardiac magnetic resonance. Of the remaining
99 asymptomatic athletes, 12 (12%) had a wall thickness greater
than 12 mm and 18 (18%) had an LVIDd greater than 60 mm.
However, in the presence of a normal ECG, absence of systolic
anterior motion of the anterior mitral valve leaﬂet causing LV
outﬂow obstruction, an appropriately dilated LV, and normal dia-
stolic function, a diagnosis of HCM was excluded in all athletes.
This study suggests that irrespective of an athlete’s enlarged BSA,
the upper limit of physiological maximal wall thickness remains in
the 13–16 mm range. Indeed, our data support the more conserva-
tive approach limits suggested by Whyte et al4 such that regardless
of extreme body anthropometry, the physiological upper normal
limits of LV wall thickness and LVIDd are 14 and 65 mm,
respectively.
Despite being referred for echocardiography due to a clinical
suspicion of possible cardiac disease based on an abnormal
ECG, family history or clinical evaluation, two studies are
worthy of mention that support our data in ‘big’ athletes.
Abernethy et al12 investigated 156 asymptomatic American
Football (NFL) players and reported mean maximal wall
thickness and LVIDd to be 11.2±0.2 and 53±0.5 mm, respect-
ively. While Magalski et al11 observed that from 203 referred
NFL athletes, 197 (97%) demonstrated a maximal IVSd from 7
to 12 mm, with six athletes (3%) presenting an IVSd from 13
to 14 mm. However, all 203 were considered not to have a car-
diomyopic process due to no other echocardiographic abnormal-
ities and normal Doppler inﬂow velocities.
It is well recognised that little account of body size is taken in
the determination of ‘apparently normal’ cardiac dimensions in
adult athletes, even though allometric scaling in the paediatric
population is routine practice.36 Despite the strong relationships
between BSA and multiple LV measures in the current study, abso-
lute upper normal limits are still clinically relevant. It may be that
scaling, via an appropriate method and scaling variable, maybe be
of more clinical value in those athletes with smaller BSA’s.
Recent data suggest that an athlete’s ethnic origin may have
a signiﬁcant impact on their cardiovascular response to exer-
cise.13 35 37 Despite no signiﬁcant difference in BSA between
ethnicities in the >2.3 m2 cohort of athletes, Black African ath-
letes presented signiﬁcantly greater wall thicknesses, and result-
ant LV masses, than West-Asian and Caucasian athletes. It
should be noted that regardless of ethnicity and the extreme
BSA of this cohort, the established upper limits of cardiac struc-
ture and function are applicable to all three ethnicities. Previous
data from our group have demonstrated that a minority
Table 4 Impact of ethnicity upon cardiac structure and function in athletes with a BSA>2.3m2 (mean±SD; range)
West-Asian Black African Caucasian
N=31 N=45 N=23
Height (cm) 189±8 (170–206) 201±7 (182–217) 199±7 (180–210)
Body mass (kg) 109±14 (91–150) 105±12 (85–156) 101±8 (87–117)
Body surface area (m2) 2.4±0.1 (2.3–2.6) 2.4±0.1 (2.3–3.0) 2.4±0.1 (2.3–2.6)
Aortic diameter (mm) 30±2 (25–33) 30±2 (26–35) 30±2 (26–34)
LA (mm) 37±4 (30–45) 37±4 (28–45) 37±4 (29–48)
LA area (mm2) 22±3 (14–30) 23±3 (16–29) 22±4 (14–33)
LA volume (ml) 61±15 (23–91) 71±16** (36–103) 60±18 (31–98)
Right atrial area (mm2) 19±4 (12–28) 21±3** (12–28) 19±3 (13–24)
Interventricular septum thickness in diastole (mm) 10±1 (7–12) 11±1* (8–13) 10±1 (7–13)
LVID in diastole (mm) 60±1*** (48–60) 57±1 (50–63) 58±1 (54–63)
Posterior wall thickness in diastole (mm) 9±0.2 (7–12) 10±0.2* (7–13) 9±0.2 (8–10)
LVID in systole (mm) 39±5 (28–46) 40±5 (26–50) 41±3 (36–46)
LV end diastolic volume (ml) 147±32 (88–236) 157±24 (109–209) 161±36 (120–271)
LVE end systolic volume (ml) 48±12 (22–76) 51±10 (34–75) 54±16 (30–111)
LV mass (g) 208±33 (140–276) 236±43** (146–348) 217±27 (164–266)
*Significant difference between Black athletes versus West-Asian and Caucasian athletes (p<0.05).
**Significant difference between Black athletes versus West-Asian athletes (p<0.05).
***Significant difference between West-Asian athletes versus Caucasian athletes (p<0.05).
LA, left atrial diameter; LVIDd, left ventricular internal diameter.
Figure 2 Relationship between the
athlete’s body surface area and their
systolic blood pressure.
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(3%) of Black athletes (mean BSA 2.1 m2; 9 from 300) may
present physiological LVH≥15 mm.34 The present data set of
219 Black African athletes from a broad range of BSA’s did not
ﬁnd an athlete with a normal ECG presenting a maximal wall
thickness greater than 13 mm. A limitation of the present
study is that a data set of 46 Black African with a BSA>2.3 m2
maybe too small to ascertain if this ethnicity with extreme
anthropometry requires the upper limits of physiological LVH
to be raised to 15 mm; in spite of demonstrating signiﬁcantly
greater wall thicknesses and masses that their West-Asian and
Caucasian counterparts. Interestingly, Basavarajaiah et al35
study demonstrated that basal and exercise-related BP responses
in both Black and Caucasian athletes did not differ and could
not explain the increased magnitude of LVH in Black athletes.
At the time, we suggested that a combination of genetic,38
endocrine and haemodynamic factors39 probably accounts for
the increased LVH in black athletes. Yet to date, no data have
been published to conﬁrm this postulation. Second, while pro-
fessional basketball, handball and volleyball players were
recruited, substantiation of the upper limits of physiological
LVH is required in the small minority of athletes with extreme
BSA’s who compete in sports that induce the greatest amounts
of cardiac remodelling; namely rowing, cycling, cross-country
skiing, biathlon. Nevertheless, this will once again prove prob-
lematic for the Black African ethnicity whose participation in
these endurance sports is limited.
Regardless of these limitations, our data support the clinical
utility of ECG in the initial identiﬁcation of athletes suspected of
harbouring an inherited cardiac disease. The present study diag-
nosed one athlete with a mild variant of apical HCM via cardiac
magnetic resonance, following an abnormal ECG suggestive of an
inherited cardiac disease. This was in spite of a normal echocar-
diogram (maximal LV wall thickness of 8 mm). In conclusion,
marked repolarisation changes, ST depression, pathological Q
waves and multiple ventricular ectopic’s are a great concern, even
when cardiac dimensions are within accepted limits.
In conclusion, irrespective of an athlete’s extreme anthropo-
metrical dimensions and ethnicity, the physiological upper
normal limits of LV wall thickness and LV internal diameter
during diastole due to intensive and sustained physical activity
are 14 and 65 mm, respectively. Moreover, even when matched
for extreme BSA (>2.3 m2), Black African athletes present sig-
niﬁcantly greater wall thicknesses and resultant LV masses
than Arabic and Caucasian athletes.
What this study adds
▸ Regardless of extreme body surface area (BSA), no
asymptomatic athlete with a negative family history of
sudden cardiac death and a normal ECG presented a
maximal wall thickness >14 mm.
▸ Established upper limits for physiological cardiac
hypertrophy of 14 mm for maximal wall thickness and
65 mm for left ventricular internal diameter during diastole
are appropriate, irrespective of an athlete’s BSA.
▸ We identiﬁed one athlete with a cardiomyopathy with
normal wall thicknesses on echocardiography but abnormal
cardiac magnetic resonance. The ECG remains key and
should guide follow-up management. Marked repolarisation
changes, ST depression, pathological Q waves and multiple
ventricular ectopic’s are a great concern, even when cardiac
dimensions are within accepted limits on echocardiography.
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